- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02266784
Contingency Management, Quitting Smoking, and ADHD (ADQUIT)
Smoking/Nicotine Dependence in Attention Deficit Hyperactivity Disorder (ADHD)
The overall goal of the study is to evaluate how motivation and readiness for change are influenced in the context of a smoking cessation attempt. A total of 60 adult (i.e. age 18-55) smokers (N=40 with ADHD; N=20 without ADHD) who are interested in quitting will be enrolled into a 3-arm trial allocated as follows. Twenty of the ADHD smokers and the 20 non-ADHD smokers will be assigned to a traditional 8-week contingency management intervention in which monetary payments will be made contingent upon biologically verified evidence of smoking abstinence. The 20 additional ADHD smokers will be assigned to a treatment-as-usual condition (nicotine replacement; supportive counseling). During the treatment phase, subjects will be required to answer questions 4x/week in their daily lives via an EMA (Ecological Momentary Assessment).
Specific Aim 1: To assess motivation to quit smoking and readiness for change prior to a quit attempt in treatment seeking ADHD and non-ADHD smokers. Hypothesis 1a: The investigators hypothesize that prior to a quit attempt, smokers with ADHD will exhibit significantly lower levels of intrinsic motivation to quit, and equal or higher levels of extrinsic motivation to quit compared to smokers without ADHD. Hypothesis 1b: The investigators hypothesize that smokers with ADHD will exhibit relatively less readiness for change than smokers without ADHD.
Specific Aim 2: To assess how baseline levels of motivation to quit and readiness for change are influenced during a quit attempt as a function of both ADHD status and treatment modality. Hypothesis 2a. The investigators hypothesize that the CM intervention will result in relatively greater change in extrinsic motivation to quit versus intrinsic motivation to quit, and that this effect will be more pronounced among ADHD smokers. Hypothesis 2b: The investigators hypothesize that overall motivation to quit (intrinsic and extrinsic) and readiness for change will be significantly influenced by the CM intervention versus treatment as usual among ADHD smokers.
Exploratory Aim 1: To assess the relative efficacy of a CM intervention versus treatment as usual in smokers with ADHD. The investigators hypothesize that CM will be more effective for promoting short-term (4-8 weeks) smoking abstinence, as well as for promoting longer-term (3-6 months) smoking cessation.
Exploratory Aim 2: To assess the associations among smoking withdrawal/craving, affect, ADHD symptoms, and motivation to quit/readiness for change. The investigators hypothesize that higher levels of motivation and readiness for change will be associated with lower levels of self-reported withdrawal, craving, and negative affect.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke Child and Family Study Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-55 years of age
- Male or female; if female of child-bearing potential, must be using an acceptable form of contraception
- ADHD Diagnosis:
- For ADHD Groups: confirmed primary diagnosis, any subtype as determined by the clinician administered CAADID and clinical interview
- For Control Group: NO diagnosis of ADHD as determined by clinician administered CAADID and clinical interview
- ADHD Symptom Ratings:
- For ADHD Groups: T-Score > 65 on one of the DSM-IV relevant scales (Inattentive Symptoms, Hyperactive-Impulsive Symptoms, Total Symptoms or ADHD Index) on both the Self-Report and Observer versions of the CAARS
- For Control Group: T-Score < 60 on all of the DSM-IV relevant scales (Inattentive Symptoms, Hyperactive-Impulsive Symptoms, Total Symptoms or ADHD Index) on both the Self-Report and Observer versions of the CAARS
- Self-report smoking at least 10 cigarettes/day
- Provides an afternoon exhaled carbon monoxide reading of at least 10 ppm.
- Cognitive functioning > 80 as assessed by the KBIT-II
Exclusion Criteria:
- History of chronic/significant medical condition
- Use of any psychoactive medication in the past 12 months, other than FDA-approved medication for the ADHD group only
- Estimated IQ < 80 on Kaufmann Brief Intelligence Test, Second Edition
- Has a primary diagnosis of any other Axis I Disorder (determined by the Structured Diagnostic Interview for DSM; SCID) that is significantly impairing and would contraindicate participation in the present study
- Has a primary diagnosis of any Axis II Disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Contingency Management (CM)
ADHD (N=20) & CTRL (N=20).
Participants will earn compensation, based upon smoking abstinence via a Contingency Management (CM) system.
This level of compensation will increase by the same amount each visit based upon abstinence.
In addition, escalating bonus payments will be available for evidence of continued abstinence.
The first 10 visits will be daily weekdays.
The following 9 visits will be over three weeks.
The final 3 treatment visits will occur weekly.
The 2nd & 3rd type visits CM payments will be based upon monitoring participants' cotinine levels.
A missed visit or elevated CO level will lead to 1) no CM payment for that day; 2) resetting the contingencies such that the next CO sample that is below the criterion will result in payment equal to the first day.
If there is a lapse, participants' contingencies will be reinstated at their previous highest level post 3 abstinent days.
Also follow-up visits at 3 and 6 months.
|
|
OTHER: Treatment as Usual
ADHD (N=20).
Transdermal nicotine skin patches (i.e.
Habitrol) will be used along with supportive counseling in the treatment as usual groups.
Visit schedules will coincide with the visit schedules for the CM groups (daily visits for 1st 2 weeks, 3X weekly visits for weeks 3-5, 1x weekly visit for weeks 6-8).
A standard regimen of nicotine replacement with which the study team has experience will be used: four weeks of 21 mg/d beginning on the QD, two weeks of 14 mg/d and two weeks of 7 mg/d.
Also follow-up visits at 3 and 6 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in motivation to quit smoking, as measured by the Readiness to Change Questionnaire
Time Frame: Baseline to 9 weeks
|
During the treatment period, participants will answer at least 4 times weekly, questionnaires to assess motivation for behavior change, autonomy, and interest in quitting.
The Readiness to Change Questionnaire (RCQ) is a measure designed to assess attitudes toward quitting smoking.
|
Baseline to 9 weeks
|
Change in motivation to quit smoking, as measured by the Treatment Self-Regulation Questionnaire
Time Frame: Baseline to 9 weeks
|
During the treatment period, participants will answer at least 4 times weekly, questionnaires to assess motivation for behavior change, autonomy, and interest in quitting.
The Treatment Self-Regulation Questionnaire measures autonomous motivation.
|
Baseline to 9 weeks
|
Change in motivation to quit smoking, as measured by the Perceived Competence Scale for Cessation
Time Frame: Baseline to 9 weeks
|
During the treatment period, participants will answer at least 4 times weekly, questionnaires to assess motivation for behavior change, autonomy, and interest in quitting.
The Perceived Competence Scale for Cessation measures perceived competence to quit.
|
Baseline to 9 weeks
|
Change in motivation to quit smoking, as measured by the Reasons For Quitting questionnaire
Time Frame: Baseline to 9 weeks
|
During the treatment period, participants will answer at least 4 times weekly, questionnaires to assess motivation for behavior change, autonomy, and interest in quitting.
The Reasons For Quitting questionnaire measures relative levels of intrinsic versus extrinsic motivation to quit smoking.
|
Baseline to 9 weeks
|
Change in readiness to change behavior, as measured by the Readiness to Change Questionnaire
Time Frame: Baseline to 9 weeks
|
During the treatment period, participants will answer at least 4 times weekly, questionnaires to assess motivation for behavior change, autonomy, and interest in quitting.
The Readiness to Change Questionnaire (RCQ) is a measure designed to assess attitudes toward quitting smoking.
|
Baseline to 9 weeks
|
Change in readiness to change behavior, as measured by the Treatment Self-Regulation Questionnaire
Time Frame: Baseline to 9 weeks
|
During the treatment period, participants will answer at least 4 times weekly, questionnaires to assess motivation for behavior change, autonomy, and interest in quitting.
The Treatment Self-Regulation Questionnaire measures autonomous motivation.
|
Baseline to 9 weeks
|
Change in readiness to change behavior, as measured by the Perceived Competence Scale for Cessation
Time Frame: Baseline to 9 weeks
|
During the treatment period, participants will answer at least 4 times weekly, questionnaires to assess motivation for behavior change, autonomy, and interest in quitting.
The Perceived Competence Scale for Cessation measures perceived competence to quit.
|
Baseline to 9 weeks
|
Change in readiness to change behavior, as measured by the Reasons For Quitting questionnaire
Time Frame: Baseline to 9 weeks
|
During the treatment period, participants will answer at least 4 times weekly, questionnaires to assess motivation for behavior change, autonomy, and interest in quitting.
The Reasons For Quitting questionnaire measures relative levels of intrinsic versus extrinsic motivation to quit smoking.
|
Baseline to 9 weeks
|
Comparison of populations in motivation to quit on the Reasons for Quitting Questionnaire
Time Frame: Baseline to 9 weeks
|
The study team will compare the change in scores for extrinsic and intrinsic motivation to quit on the Reasons for Quitting Questionnaire in the ADHD and non-ADHD groups assigned to receive CM.
|
Baseline to 9 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in smoking behavior in ADHD population
Time Frame: Baseline, 3 months, 6 months
|
This outcome is based both upon the treatment period and follow-up visits at 3 and 6 months.
CM is proposed to be a potential more effective treatment in an ADHD population in the short and longer term, in comparison to treatment as usual.
This will be measured by urine cotinine level and residual Carbon Monoxides levels from samples provided by participants.
|
Baseline, 3 months, 6 months
|
Decreasing effects of quitting smoking.
Time Frame: Baseline, 3 months, 6 months
|
This outcome assesses overall whether increased motivation and readiness for behavior change (i.e.
quit smoking), potentially associated CM, will decrease negative aspects of quitting.
These include smoking withdrawal/craving, affect, and impact on ADHD symptoms.
|
Baseline, 3 months, 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Scott H Kollins, Ph.D., Duke Health
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00055228
- 2K24DA023464-06A1 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
-
University of Wisconsin, MadisonCentiment LLCCompletedSmoking | Smoking CessationUnited States
-
Yale UniversityCompletedSmoking | Smoking CessationUnited States
-
Johns Hopkins UniversityMaryland Department of Health and Mental HygieneCompletedCOach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation (C2Q)Smoking | Smoking CessationUnited States
Clinical Trials on Contingency Management (CM)
-
VA Office of Research and DevelopmentRecruitingPTSD | Cannabis-Related DisorderUnited States
-
NYU Langone HealthNational Institute of Mental Health (NIMH)CompletedAttention Deficit Disorder With HyperactivityUnited States
-
Oregon Social Learning CenterActive, not recruiting
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)CompletedAdolescent Substance UseUnited States
-
UConn HealthNational Institute of Mental Health (NIMH)Completed
-
Yale UniversityNational Cancer Institute (NCI)Completed
-
Oregon Health and Science UniversityOregon Health Authority; Comagine HealthRecruitingMethamphetamine AbuseUnited States
-
Washington State UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
University of OklahomaM.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Florida and other collaboratorsRecruiting
-
Dartmouth-Hitchcock Medical CenterNational Institute on Drug Abuse (NIDA); Johns Hopkins University; University... and other collaboratorsCompleted